Data from Pharmawand - Curated by EPG Health - Date added 25 December 2017

In draft guidelines, the National Institute for Health and Care Excellence (NICE) notes that treatment options for patients with metastatic urothelial cancer, whose disease has progressed after platinum-based chemotherapy including docetaxel, paclitaxel or best supportive care, and that evidence from two clinical trials suggests that atezolizumab is an effective therapy.

However the cost of Tecentriq (atezolizumab) “is very high relative to the benefits it provides,” NICE said, and also highlighted “uncertainties in the economic model”, including how long people take the drug for and its long-term benefits. Tecentriq does meet NICE’s criteria to be considered a life-extending treatment at the end of life, but the most plausible cost-effectiveness estimate is much higher than what the Institute normally considers acceptable for end-of-life treatments and so it is not recommended for routine use in the NHS.

Comments

You will need to login, to leave a comment.

epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Fluid Management

Fluid Management

Are you up-to-date with the latest evidence of effective procedures for fluid management?

+ 2 more

Cushing's Syndrome

Cushing's Syndrome

Cushing’s syndrome shares symptoms such as hypertension, glucose intolerance and obesity with other common conditions – how can you confidently diagnose this rare disorder?

+ 2 more

Load more

Related Content